日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multi-model approach identifies ALW-II-41-27 as a promising therapy for osteoarthritis-associated inflammation and endochondral ossification

多模型分析表明,ALW-II-41-27 是一种有前景的治疗骨关节炎相关炎症和软骨内成骨的药物。

Mauricio N Ferrao Blanco ,Raphaelle Lesage ,Nicole Kops ,Niamh Fahy ,Fjodor T Bekedam ,Athina Chavli ,Yvonne M Bastiaansen-Jenniskens ,Liesbet Geris ,Mark G Chambers ,Andrew A Pitsillides ,Roberto Narcisi ,Gerjo J V M van Osch

A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases

非消耗性抗 CD19 抗体可损害 B 细胞功能并抑制自身免疫性疾病

Jeffrey S Boyles, Dorota Sadowski, Scott Potter, Aleksandra Vukojicic, James Parker, William Y Chang, Yanfei L Ma, Mark G Chambers, James Nelson, Barbra Barmettler, Eric M Smith, Kara Kersjes, Evan R Himes, Chaohua Lin, Jonathan Lucchesi, Jaladhi Brahmbhatt, Ramtin Sina, Jennifer A Martin, Evan Maes

Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists

新型、选择性、强效 EP4 受体拮抗剂的镇痛和抗炎特性

Srinivasan Chandrasekhar, Xiao-Peng Yu, Anita K Harvey, Jennifer L Oskins, Chaohua Lin, Xushan Wang, Maria-Jesus Blanco, Matthew J Fisher, Steven L Kuklish, Matthew A Schiffler, Tatiana Vetman, Alan M Warshawsky, Jeremy S York, Alison M Bendele, Mark G Chambers

Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design

使用基于结构的药物设计鉴定用于治疗骨关节炎疼痛的有效且选择性的视黄酸受体γ(RARγ)拮抗剂

Norman E Hughes, Thomas J Bleisch, Scott A Jones, Timothy I Richardson, Robert A Doti, Yong Wang, Stephanie L Stout, Gregory L Durst, Mark G Chambers, Jennifer L Oskins, Chaohua Lin, Lisa A Adams, Todd J Page, Robert J Barr, Richard W Zink, Harold Osborne, Chahrzad Montrose-Rafizadeh, Bryan H Norman